Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Lamotrigin

Klassificering: C

Preparat: Crisomet, Labileno, Lamictal, Lamictal 25 mg disperguojamosios, Lamictal®, Lamocare, Lamotrigin 1A Farma, Lamotrigin 2care4, Lamotrigin Actavis, Lamotrigin Amneal, Lamotrigin Arrow, Lamotrigin Aurobindo, Lamotrigin Bluefish, Lamotrigin BMM Pharma, Lamotrigin Copyfarm, Lamotrigin Ebb, Lamotrigin EQL, Lamotrigin Hexal, Lamotrigin Medochemie, Lamotrigin Mylan, Lamotrigin Omnia, Lamotrigin Orifarm, Lamotrigin ratiopharm, Lamotrigin Teva

ATC kod: N03AX09

Substanser: lamotrigin

Sammanfattning

Det saknas studier som jämför den krampförebyggande effekten mellan män och kvinnor. En studie har visat att män svarar bättre än kvinnor på behandling med lamotrigin vid svårbehandlad bipolär affektiv sjukdom.

Den övergripande biverkningsprofilen för lamotrigin är likartad för män och kvinnor. Yrsel har i en studie rapporterats vara vanligare hos kvinnor.

Under graviditet sjunker vanligen koncentrationen av lamotrigin, tät monitorering av detta och korrigering av dos krävs för att upprätthålla krampförebyggande effekt. Post-partum måste dosen normaliseras för att undvika överdosering.

Additional information

Pharmacokinetics and dosing

Population analysis shows that pharmacokinetics of lamotrigine are similar in men and women [1,2,3,]. However, a meta-analysis found that the volume of distribution was 27% lower in women than men. This difference persisted even when the effect of weight was taken into account. Totally 22/289 women were receiving concomitant therapy with various oral contraceptives. But in this study, oral contraceptives exhibited little effect on the pharmacokinetics of lamotrigine [3]. Dose adjustment based on sex appear to be unnecessary [2,3].

During pregnancy, clearance of lamotrigine increases progressively until the 32nd gestational week when it may be 2-3 times higher than pre-pregnancy levels. This is caused by induction of glucuronidation. After delivery the lamotrigine elimination rate drops rapidly and reach the pre-pregnant levels within the first 2-3 weeks postpartum [3,4]. During mid and late pregnancy, serum concentrations of lamotrigine may decline to 30-50% of pre-pregnancy levels, with an increased frequency of seizures [4,5]. Therefore, close monitoring of lamotrigine concentrations throughout the entire pregnancy and postpartum is recommended [6].

Effects

A randomized clinical trial (18 men, 27 women) studying possible clinical predictors of positive response to lamotrigine monotherapy in adults with refractory affective bipolar disorder found a relationship between the degree of lamotrigine response and male sex [7].

Adverse effects

In a randomized parallel study comparing placebo and 300 and 500 mg/day of lamotrigine, the overall adverse reaction profile for lamotrigine was similar between females and males. The only adverse reaction for which the reports were greater than 10% more frequent in females than males was dizziness (difference = 16.5%) [1]. A retrospective analysis of patients on antiepileptic drug treatment showed fertile women to have a higher risk for skin reactions than men when treated with lamotrigine [8].

Drug interactions

Lamotrigine has little effect on mixed-function oxygenase enzymes, it would not be expected that estrogen and progestin clearance would be altered. Previous investigation suggests that lamotrigine has no effect on the clearance of ethinyl estradiol and levonorgestrel (30/150 mikrogram) and no alternations in menstrual pattern were noted [5]. Swedish users, please consult Janusmed Interactions(Janusmed interaktioner).

Birth defects

Swedish users, please consult Janusmed Drugs and Birth Defects(Janusmed fosterpåverkan).

Försäljning på recept

Fler kvinnor än män hämtade ut tabletter innehållande lamotrigin (ATC-kod N03AX09) på recept i Sverige år 2015, totalt 30 197 kvinnor och 18 439 män. Det motsvarar 6,2 respektive 3,8 personer per tusen invånare. Andelen som hämtat ut läkemedel var högst i åldersgruppen 25-34 år hos båda könen. I genomsnitt var tabletter innehållande lamotrigin 1,6 gånger vanligare hos kvinnor [9].

Uppdaterat: 2017-03-28

Litteratursökningsdatum: 2013-03-20

Referenser

  1. Lamotrigine. DailyMed [www]. US National Library of Medicine. [updated 2012-10-01, cited 2013-03-18]. länk
  2. Hussein Z, Posner J. Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br J Clin Pharmacol. 1997;43:457-65. PubMed
  3. Grasela TH, Fiedler-Kelly J, Cox E, Womble GP, Risner ME, Chen C. Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy. J Clin Pharmacol. 1999;39:373-84. PubMed
  4. Sabers A, Tomson T. Managing antiepileptic drugs during pregnancy and lactation. Curr Opin Neurol. 2009;22:157-61. PubMed
  5. Schenck-Gustafsson K, DeCola PR, Pfaff DW, Pisetsky DS, editor. Handbook of Clinical Gender Medicine. 1st ed. Karger; 2012.
  6. Pennell PB. 2005 AES annual course: evidence used to treat women with epilepsy. Epilepsia. 2006;47 Suppl 1:46-53. PubMed
  7. Obrocea GV, Dunn RM, Frye MA, Ketter TA, Luckenbaugh DA, Leverich GS et al. Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biol Psychiatry. 2002;51:253-60. PubMed
  8. Alvestad S, Lydersen S, Brodtkorb E. Rash from antiepileptic drugs: influence by gender, age, and learning disability. Epilepsia. 2007;48:1360-5. PubMed
  9. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-04-30.] länk

Författare: Linnéa Karlsson Lind, Desirée Loikas

Faktagranskat av: Expertrådet för neurologiska sjukdomar, Ellen Vinge

Godkänt av: Mia von Euler